<description>&lt;h3&gt;&lt;span&gt;Episode Summary:&lt;/span&gt;&lt;/h3&gt;&lt;p&gt;&lt;span&gt;In this episode of &lt;/span&gt;&lt;em&gt;First Cheque&lt;/em&gt;&lt;span&gt;, hosts Cheryl Mack and Maxine Minter sit down with biotech investment expert Paul Kelly. The conversation demystifies the complex world of biotech investing, making it accessible for even those who are new to the field. Paul shares his journey from a practising physician to a pioneering investor in the biotech space, offering valuable insights into the industry&amp;#39;s rapid evolution and high stakes.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;Paul explains the fundamentals of biotech investing, including the typical risks and rewards, the lengthy timeframes involved, and the importance of understanding the science and market potential behind each investment. He also touches on the significant advances in genomics and synthetic biology, emphasising how technology and data analysis are accelerating innovation in the field. The discussion delves into the importance of syndication for early-stage investments, the critical milestones that de-risk investments, and the role of pharmaceutical partnerships in increasing the likelihood of success.&lt;/span&gt;&lt;/p&gt;&lt;h3&gt;&lt;span&gt;Key Takeaways:&lt;/span&gt;&lt;/h3&gt;&lt;ul&gt;&lt;li&gt;&lt;strong&gt;Understand the Risks and Rewards&lt;/strong&gt;&lt;span&gt;: Biotech investing involves a high level of risk and typically long hold periods, but the potential rewards can be substantial.&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;strong&gt;Syndicate Investments&lt;/strong&gt;&lt;span&gt;: Due to the complexity and capital intensity of biotech, syndicating with experienced investors and funds is crucial for mitigating risk.&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;strong&gt;Stages of Investment&lt;/strong&gt;&lt;span&gt;: Key milestones in biotech investing include achieving safety and efficacy in clinical trials, with significant value inflections at each stage.&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;strong&gt;Technological Impact&lt;/strong&gt;&lt;span&gt;: Advances in genomics, AI, and data analysis are revolutionizing the speed and accuracy of biotech innovations.&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;strong&gt;Healthcare Economics&lt;/strong&gt;&lt;span&gt;: Understanding the economic impact and potential reimbursement scenarios is essential for assessing biotech investments.&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;br/&gt;&lt;h3&gt;&lt;br&gt;&lt;/h3&gt;&lt;h3&gt;Sponsors:&lt;/h3&gt;&lt;p&gt;Thanks to our sponsors for helping to make this episode of First Cheque possible.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Vanta:&lt;/strong&gt; Join 7,000 global companies like Atlassian and Dovetail that use Vanta to build trust and prove security in real-time. Get 10% off &lt;a href="https://dayone.fm/vanta" rel="nofollow"&gt;https://dayone.fm/vanta&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Scendar:&lt;/strong&gt; Scendar is the OG startup accounting firm in Australia. Free 1-hour consultation about your Business&amp;#39; growth plans and finance needs. &lt;a href="https://dayone.fm/scendar" rel="nofollow"&gt;https://dayone.fm/scendar&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Turo:&lt;/strong&gt; Turo is the world&amp;#39;s largest carsharing marketplace and it&amp;#39;s the perfect app for travel.&lt;/p&gt;&lt;p&gt;Download the Turo app and book cars from $38/day. &lt;a href="https://dayone.fm/turo" rel="nofollow"&gt;https://dayone.fm/turo&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;h2&gt;The Day One Network&lt;/h2&gt;&lt;h3&gt;First Cheque is part of Day One, the podcast network dedicated to founders, operators &amp;amp; investors.&lt;/h3&gt;&lt;p&gt;To learn more, join our &lt;a href="https://dayone.fm/podcast-network/newsletter/" rel="nofollow"&gt;newsletter&lt;/a&gt; to be notified of new and upcoming shows. The only content we create is content that will help Australian founders.&lt;/p&gt;&lt;p&gt;If you want to learn about upcoming guests and when a new First Cheque episode is available, join the &lt;a href="https://dayone.fm/podcast-network/first-cheque/newsletter" rel="nofollow"&gt;First Cheque newsletter&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Mentioned in this episode:&lt;/p&gt;&lt;p&gt;&lt;a href="https://first-cheque-dayone.captivate.fm/vanta"&gt;June 2024 – Vanta First Cheque&lt;/a&gt;&lt;/p&gt;&lt;br/&gt;&lt;br/&gt;This podcast uses the following third-party services for analysis: &lt;br/&gt;&lt;br/&gt;Spotify Ad Analytics - https://www.spotify.com/us/legal/ad-analytics-privacy-policy/</description>

First Cheque

DayOne.fm

From Scalpel to Syndicate: Paul Kelly's Guide to Navigating Biotech Investing

AUG 25, 202459 MIN
First Cheque

From Scalpel to Syndicate: Paul Kelly's Guide to Navigating Biotech Investing

AUG 25, 202459 MIN

Description

Episode Summary:

In this episode of First Cheque, hosts Cheryl Mack and Maxine Minter sit down with biotech investment expert Paul Kelly. The conversation demystifies the complex world of biotech investing, making it accessible for even those who are new to the field. Paul shares his journey from a practising physician to a pioneering investor in the biotech space, offering valuable insights into the industry's rapid evolution and high stakes.

Paul explains the fundamentals of biotech investing, including the typical risks and rewards, the lengthy timeframes involved, and the importance of understanding the science and market potential behind each investment. He also touches on the significant advances in genomics and synthetic biology, emphasising how technology and data analysis are accelerating innovation in the field. The discussion delves into the importance of syndication for early-stage investments, the critical milestones that de-risk investments, and the role of pharmaceutical partnerships in increasing the likelihood of success.

Key Takeaways:

  • Understand the Risks and Rewards: Biotech investing involves a high level of risk and typically long hold periods, but the potential rewards can be substantial.
  • Syndicate Investments: Due to the complexity and capital intensity of biotech, syndicating with experienced investors and funds is crucial for mitigating risk.
  • Stages of Investment: Key milestones in biotech investing include achieving safety and efficacy in clinical trials, with significant value inflections at each stage.
  • Technological Impact: Advances in genomics, AI, and data analysis are revolutionizing the speed and accuracy of biotech innovations.
  • Healthcare Economics: Understanding the economic impact and potential reimbursement scenarios is essential for assessing biotech investments.


Sponsors:

Thanks to our sponsors for helping to make this episode of First Cheque possible.

Vanta: Join 7,000 global companies like Atlassian and Dovetail that use Vanta to build trust and prove security in real-time. Get 10% off https://dayone.fm/vanta

Scendar: Scendar is the OG startup accounting firm in Australia. Free 1-hour consultation about your Business' growth plans and finance needs. https://dayone.fm/scendar

Turo: Turo is the world's largest carsharing marketplace and it's the perfect app for travel.

Download the Turo app and book cars from $38/day. https://dayone.fm/turo


The Day One Network

First Cheque is part of Day One, the podcast network dedicated to founders, operators & investors.

To learn more, join our newsletter to be notified of new and upcoming shows. The only content we create is content that will help Australian founders.

If you want to learn about upcoming guests and when a new First Cheque episode is available, join the First Cheque newsletter.

Mentioned in this episode:

June 2024 – Vanta First Cheque



This podcast uses the following third-party services for analysis:

Spotify Ad Analytics - https://www.spotify.com/us/legal/ad-analytics-privacy-policy/